• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

New gene associated with essential thrombocytopenia and primary myelofibrosis

bys25qthea
December 11, 2013
in Chronic Disease, Genetics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Mutations in the gene encoding calreticulin (CALR) were found in a majority of patients with non-JAK2, non-MPL essential thrombocythemia or primary myelofibrosis.

2. Patients with CALR mutations may have a more benign clinical course.

Study Rundown: The majority of patients with essential thrombocythemia (ET) or primary myelofibrosis (PM) have been shown to carry mutations in the Janus kinase 2 gene (JAK2) or the thrombopoietin receptor gene (MPL). However, no mutations have yet been identified in 30 to 45% of cases. In this study, the authors used whole-exome sequencing to look for new mutations associated with ET and PM. CALR was found to be mutated in the six patients sequenced. No other genes were identified in the screen.

Targeted sequencing of CALR in a cohort of patients with myeloproliferative disease showed that the prevalence of CALR mutations was quite high. Around 25 to 35% of cases of ET and PM were associated with CALR mutations, making it the second most common mutation in these diseases. Furthermore, the CALR mutations were mutually exclusive with JAK2 and MPL mutations. In a retrospective analysis, CALR mutations appeared to be associated with a more benign course, with better overall survival compared to patients with JAK2 or MPL mutations.

Functional significance is implied by in vitro experiments showing that cells with the mutant CALR gene grow independently of cell growth signals.  However, more work is needed to establish the pathogenic mechanism of the CALR mutations.

Click to read the study in NEJM

RELATED REPORTS

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma

2 Minute Medicine Rewind June 27, 2022

Click to read the accompanying editorial in NEJM

Relevant Reading: Calreticulin in the immune system: ins and outs

In-Depth [in vitro genetic study]:  Thirty-six different CALR mutations were identified. The majority of these mutations were a 52bp deletion (53%) and a 5bp insertion (31.7%). All of the 36 mutations produced a frameshift to the same alternative reading frame, which results in a mutant protein lacking an endoplasmic reticulum-retention signal. Indeed, the authors demonstrated altered subcellular localization of the mutant protein using immunofluorescence.

It is interesting that all the CALR mutations identified involved a frameshift to the same alternative reading frame. This may suggest that the pathogenicity of the mutant protein is related to altered subcellular localization rather than loss of function.

The authors also show that STAT5 phosphorylation is increased in a cytokine-independent manner in cell lines transfected with the mutant CALR. Although the authors report that the cells with mutant CALR are sensitive to a JAK2 inhibitor, it would have been useful to evaluate the phosphorylation of STAT5 in the presence and absence of the JAK2 inhibitor to tease apart the mechanistic pathway.

By Tomi Jun and Adrienne Cheung

More from this author: Early risk factor for progression of cystic fibrosis identified, Gut microbes implicated in stroke and heart attacks: new dietary link, New leukemia mutation offers therapeutic targets, Childhood ADHD associated with increased risk of suicide, A marker of aggressive liver cancer and potential therapeutic target identified

©2012-2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: hematologymyelofibrosisthrombocytopenia
Previous Post

PG-13/R movies similar in violence and risk behavior volume

Next Post

CPAP use linked to improvements in resistant hypertension in OSA (HIPARCO Trial)

RelatedReports

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Chronic Disease

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

June 30, 2022
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma
Chronic Disease

Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma

June 29, 2022
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Chronic Disease

2 Minute Medicine Rewind June 27, 2022

June 27, 2022
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Weekly Rewinds

2 Minute Medicine Rewind June 20, 2022

June 20, 2022
Next Post
Primary care and specialists have comparable outcomes in treating Sleep Apnea

CPAP use linked to improvements in resistant hypertension in OSA (HIPARCO Trial)

Classics Series, Landmark Trials in Medicine

IVIg with aspirin linked to reduced coronary aneurysms [Pediatrics Classics Series]

Long-term gastric acid suppression associated with vitamin B12 deficiency

Long-term gastric acid suppression associated with vitamin B12 deficiency

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.